Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care
Zest Health has secured $13 million in seed funding to address unnecessary pharmaceutical spending in dermatology care. The company focuses on treating inflammatory skin diseases through a value-based virtual care platform. With approximately 40 million Americans affected by eczema and psoriasis facing long wait times, Zest aims to reduce reliance on expensive biologics, which currently drive over $40B in annual US spend and are growing at 15% annually.
The company's virtual platform delivers personalized care, combining prescription medications, over-the-counter solutions, and lifestyle interventions. Key performance metrics include: 80% of patients showing disease improvement based on BSA and DLQI measures, 90% patient preference rate compared to prior care, and an NPS of 83. The funding, provided by Roivant Health, will support scaling partnerships with health plans and employers.
Zest Health ha ottenuto $13 milioni in finanziamenti seed per affrontare le spese farmaceutiche non necessarie nella cura dermatologica. L'azienda si concentra sul trattamento delle malattie infiammatorie della pelle attraverso una piattaforma di assistenza virtuale basata sul valore. Con circa 40 milioni di americani affetti da eczema e psoriasi che affrontano lunghi tempi di attesa, Zest mira a ridurre la dipendenza da biologici costosi, che attualmente rappresentano oltre $40 miliardi di spesa annuale negli Stati Uniti e stanno crescendo del 15% ogni anno.
La piattaforma virtuale dell'azienda offre assistenza personalizzata, combinando farmaci da prescrizione, soluzioni da banco e interventi sullo stile di vita. I principali indicatori di prestazione includono: 80% dei pazienti che mostrano miglioramenti nella malattia basati su misure BSA e DLQI, un tasso di preferenza del 90% rispetto alla cura precedente, e un NPS di 83. Il finanziamento, fornito da Roivant Health, sosterrà la scalabilità delle collaborazioni con i piani di salute e i datori di lavoro.
Zest Health ha asegurado $13 millones en financiamiento inicial para abordar el gasto farmacéutico innecesario en la atención dermatológica. La empresa se enfoca en tratar enfermedades inflamatorias de la piel a través de una plataforma de atención virtual basada en el valor. Con aproximadamente 40 millones de estadounidenses afectados por eczema y psoriasis que enfrentan largos tiempos de espera, Zest pretende reducir la dependencia de biológicos costosos, que actualmente representan más de $40 mil millones en gastos anuales en EE.UU. y están creciendo a un ritmo del 15% anual.
La plataforma virtual de la empresa ofrece atención personalizada, combinando medicamentos recetados, soluciones de venta libre e intervenciones en el estilo de vida. Los principales indicadores de rendimiento incluyen: 80% de los pacientes mostrando mejoría de la enfermedad según las medidas BSA y DLQI, una tasa de preferencia del 90% en comparación con la atención anterior, y un NPS de 83. La financiación, proporcionada por Roivant Health, apoyará la escalabilidad de colaboraciones con planes de salud y empleadores.
Zest Health는 피부과 치료에서 불필요한 제약 비용을 해결하기 위해 $13 백만의 초기 자금을 확보했습니다. 이 회사는 가치 기반의 가상 치료 플랫폼을 통해 염증성 피부 질병 치료에 집중하고 있습니다. 약 4000만 명의 미국인이 아토피 피부염과 건선으로 고통 받고 있으며 긴 대기 시간을 겪고 있어, Zest는 현재 연간 미국 지출로 $400억 이상을 차지하고 있으며 매년 15%의 성장률을 보이는 비싸고 생물학적 제재에 대한 의존도를 줄이는 것을 목표로 하고 있습니다.
회사의 가상 플랫폼은 처방약, 일반의약품 솔루션, 생활 습관 중재를 결합하여 개인화된 치료를 제공합니다. 주요 성과 지표에는 BSA 및 DLQI 측정을 기반으로 침해 개선을 보이는 환자의 80%, 이전 치료에 비해 환자 선호도 90%, NPS 83이 포함됩니다. Roivant Health가 제공한 자금은 건강 계획 및 고용주와의 파트너십 확장을 지원할 예정입니다.
Zest Health a sécurisé 13 millions de dollars dans un financement d'amorçage pour s'attaquer aux dépenses pharmaceutiques inutiles dans les soins dermatologiques. L'entreprise se concentre sur le traitement des maladies inflammatoires de la peau à travers une plateforme de soins virtuels basée sur la valeur. Avec environ 40 millions d'Américains touchés par l'eczéma et le psoriasis faisant face à de longs temps d'attente, Zest vise à réduire la dépendance à des biologiques coûteux, qui représentent actuellement plus de 40 milliards de dollars de dépenses annuelles aux États-Unis et croissent à un rythme de 15% par an.
La plateforme virtuelle de l'entreprise propose des soins personnalisés, combinant médicaments sur ordonnance, solutions en vente libre et interventions sur le mode de vie. Les principaux indicateurs de performance incluent : 80% des patients montrant une amélioration de la maladie sur la base des mesures BSA et DLQI, un taux de préférence de 90% par rapport aux soins précédents, et un NPS de 83. Le financement, fourni par Roivant Health, soutiendra l'extension des partenariats avec les régimes de santé et les employeurs.
Zest Health hat 13 Millionen Dollar in Seed-Finanzierung gesichert, um unnötige Arzneimittelausgaben in der dermatologischen Versorgung anzugehen. Das Unternehmen konzentriert sich auf die Behandlung von entzündlichen Hauterkrankungen durch eine wertbasierte virtuelle Pflegeplattform. Mit etwa 40 Millionen Amerikanern, die von Ekzemen und Psoriasis betroffen sind und langen Wartezeiten gegenüberstehen, zielt Zest darauf ab, die Abhängigkeit von teuren Biologika zu verringern, die derzeit über 40 Milliarden Dollar an jährlichen Ausgaben in den USA verursachen und mit 15% jährlich wachsen.
Die virtuelle Plattform des Unternehmens bietet personalisierte Betreuung, indem sie verschreibungspflichtige Medikamente, rezeptfreie Lösungen und Lebensstilinterventionen kombiniert. Zu den wichtigsten Leistungskennzahlen gehören: 80% der Patienten, die eine Verbesserung der Erkrankung basierend auf BSA- und DLQI-Maßnahmen zeigen, eine Patientenpräferenzquote von 90% im Vergleich zur vorherigen Behandlung und ein NPS von 83. Die Finanzierung, die von Roivant Health bereitgestellt wird, wird die Skalierung von Partnerschaften mit Gesundheitsplänen und Arbeitgebern unterstützen.
- Secured $13M seed funding from Roivant Health
- Platform achieves 80% patient improvement rate
- 90% patient preference rate vs traditional care
- High NPS score of 83
- Reduces thousands in pharmacy spend per enrollee annually
- None.
Insights
This
Market Positioning & Cost Management: Zest's platform directly addresses a critical healthcare inefficiency - the overutilization of expensive biologics in dermatology. With over 40 million Americans affected by eczema and psoriasis, the potential for cost savings is substantial. The company's approach of combining virtual care with data-driven prescription optimization could save thousands per patient annually.
Clinical Validation & Patient Satisfaction: The platform's impressive metrics -
Strategic Fit & Growth Potential: For Roivant, this investment aligns perfectly with their expertise in inflammatory diseases while expanding their footprint in digital health and value-based care. The focus on partnerships with health plans and employers provides a clear path to scalability and revenue growth. The timing is optimal as healthcare providers increasingly seek solutions to manage pharmaceutical costs without compromising care quality.
Zest is initially focused on treating the millions of Americans with inflammatory skin diseases who are currently overprescribed expensive biologics
NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zest Health, the first value-based virtual care company focused on treating patients with inflammatory skin diseases, today announced
The roughly 40 million Americans with eczema and psoriasis face average wait times of over a month and rushed visits as dermatologists increasingly turn to cash-pay models that prioritize aesthetics. To minimize and expedite office visits, prescribers rely on systemic medications to quickly achieve clear skin. Overreliance on these medications has led to rapid growth in associated spend. Biologics for these conditions are being used earlier and more chronically, growing at
Zest provides patients with more personalized, responsive care. Zest’s virtual, high-touch approach is bolstered by patient data to identify optimal prescription regimens, over-the-counter medications, lifestyle changes, and preventative interventions for more convenient, durable relief.
Zest’s approach reduces pharmacy spend by thousands of dollars per enrollee annually without sacrificing outcomes:
- Over
80% of patients see disease improvement as measured by Body Surface Area (BSA) and the Dermatology Life Quality Index (DLQI) - Over
90% of patients prefer Zest to their prior dermatology experiences - Zest has a Net Promoter Score (NPS) of 83
“As a psoriasis patient myself, I know that the status quo fails to deliver ongoing support and lasting relief,” said Zest Health CEO Olivia Deitcher. “At Zest, we have flipped traditional dermatology care on its head by providing radical access and personalized care so flaring patients get expert help during and in between flares, without overreliance on biologics.”
Roivant Health incubated and made this investment in Zest, bringing their historic expertise in inflammatory disease innovation and transformative health technologies. The funds will be used to scale Zest’s existing partnerships with health plans and employers seeking to address this growing cost pool.
“Many problems in healthcare involve challenging tradeoffs between quality and cost. This is an exception where higher quality simultaneously reduces unnecessary expense,” said Alex Gasner, EVP of Roivant Health. “We are excited at Roivant to support Zest as they use technology to bring dermatology into the 21st century.”
About Zest Health
Zest delivers more effective, accessible, and compassionate solutions for patients with chronic skin conditions like psoriasis and eczema. Through its virtual platform, Zest achieves better outcomes at a lower cost for the thousands of patients who have signed up for Zest’s services to date. Zest currently partners with health plans and employers in value-based arrangements to improve the lives of members. To learn more, please visit www.zesthealth.com.
Contact Information
press@zesthealth.com
FAQ
How much funding did Zest Health raise in its seed round?
What are the key performance metrics for Zest Health's dermatology platform?
How much does Zest Health reduce pharmaceutical spending per patient?
What is the current market size for biologics in dermatology that Zest Health is targeting?
How many Americans with skin conditions could benefit from Zest Health's platform?
